Your browser doesn't support javascript.
loading
DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells.
Loo Yau, Helen; Bell, Emma; Ettayebi, Ilias; de Almeida, Felipe Campos; Boukhaled, Giselle M; Shen, Shu Yi; Allard, David; Morancho, Beatriz; Marhon, Sajid A; Ishak, Charles A; Gonzaga, Isabela M; da Silva Medina, Tiago; Singhania, Rajat; Chakravarthy, Ankur; Chen, Raymond; Mehdipour, Parinaz; Pommey, Sandra; Klein, Christian; Amarante-Mendes, Gustavo P; Roulois, David; Arribas, Joaquín; Stagg, John; Brooks, David G; De Carvalho, Daniel D.
Afiliación
  • Loo Yau H; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
  • Bell E; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Ettayebi I; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
  • de Almeida FC; Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil; Instituto de Investigação em Imunologia, Institutos Nacionais de Ciência e Tecnologia (INCT-iii), São Paulo 05403-900, Brazil.
  • Boukhaled GM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Shen SY; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Allard D; Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada; Faculté de Pharmacie, Université de Montréal, Montréal, QC H3T 1J4, Canada.
  • Morancho B; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO) and CIBERONC, 08035 Barcelona, Spain.
  • Marhon SA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Ishak CA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Gonzaga IM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • da Silva Medina T; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Translational Immuno-oncology Laboratory, A.C. Camargo Cancer Center, São Paulo 01509-001, Brazil.
  • Singhania R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Chakravarthy A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Chen R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
  • Mehdipour P; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Pommey S; Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada.
  • Klein C; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Wagistrasse 10, 8952 Schlieren, Switzerland.
  • Amarante-Mendes GP; Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil; Instituto de Investigação em Imunologia, Institutos Nacionais de Ciência e Tecnologia (INCT-iii), São Paulo 05403-900, Brazil.
  • Roulois D; UMR U1236, INSERM, Université de Rennes 1, EFS, 35000 Rennes, France.
  • Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO) and CIBERONC, 08035 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
  • Stagg J; Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada; Faculté de Pharmacie, Université de Montréal, Montréal, QC H3T 1J4, Canada.
  • Brooks DG; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • De Carvalho DD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada. Electronic address: daniel.decarvalho@uhnresearch.ca.
Mol Cell ; 81(7): 1469-1483.e8, 2021 04 01.
Article en En | MEDLINE | ID: mdl-33609448
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Activación de Linfocitos / Linfocitos T CD8-positivos / Islas de CpG / Metilación de ADN / Granzimas / Decitabina Límite: Humans Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Activación de Linfocitos / Linfocitos T CD8-positivos / Islas de CpG / Metilación de ADN / Granzimas / Decitabina Límite: Humans Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Canadá